CA3174455A1 — Therapeutic uses of macrocyclic compounds
Assigned to Turning Point Therapeutics Inc · Expires 2021-09-10 · 5y expired
What this patent protects
This disclosure relates to the use of certain diaryl macrocycle compounds in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially i…
USPTO Abstract
This disclosure relates to the use of certain diaryl macrocycle compounds in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.
Drugs covered by this patent
- Augtyro (REPOTRECTINIB) · Bristol
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.